I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Articles
Today we’ve got a teaser pitch from Dylan Jovine’s new service, Takeover Targets, which he says is “half price” for charter subscribers (that would be $997/year, and unlike many higher-end newsletters they say they do offer refunds for 30 days)… and, as you might imagine, the service is all about identifying companies that might be […]
Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]
Happy Friday! Let’s start you out with my favorite article that I read this past week: Michael Batnick’s Twenty Craziest Investing Facts Ever. Go read it whenever you’re convinced that you know what is going to happen over the next few weeks… or even the next few years. So… what’s going on in the portfolio […]
This is an odd one, so be forewarned. A bunch of readers jumped in to ask me about emails coming out of Investorplace that pitch a tiny private company heading into FDA approval as the focus of their “Blockbuster FDA Approval Summit 2019” presentation… and yes, of course, the Mighty, Mighty Thinkolator can tell you […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Blackrock owns a bunch of shares, they didn't buy a bunch recently. Their last change, as of March 31...
Sounds like another repeat of the pitch we covered here: https://www.stockgumshoe.com/reviews/profits-unlimited/mampilly...
I am a member with Mampilly. In his latest newsletter, April 2020, he wrote: 3 Biggest stocks for phase 2 of America...
good lines or Alll-In stock...
Hi Sir, this is a good line about All-in stock...
The fools were certainly recommending DDD back in the day. 3D printing was going to change everything. Everyone would ...
Two Cdn stocks I've recently DD'd and have purchased are: Alcanna (CLIQ) and Newstrike Brands (HIP and HIP.WT.A) . I li...
In the summer of 2011 my wife and I visited her uncle in Emporium, PA who has been a successful factory rep for many yea...